BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...of Danforth Advisors, who served as interim CFO. Breuil was CFO of specialty transdermal company Corium...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Another Shire veteran, Perry Sternberg, has become CEO of Corium International Inc....
...remain chairman. The move comes about four months after affiliates of Gurnet Point Capital acquired Corium...
...Corp. (NASDAQ:QTRX). BioCentury Staff Agios Pharmaceuticals Inc. Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene N.V. Collegium Pharmaceutical Inc. Corium International Inc. Enterome...
BioCentury | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

...Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share...
...transaction, Corium will also offer to repurchase all of its $120 million in convertible notes. Corium's...
...Gurnet Point Capital, Cambridge, Mass. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Business: Neurology Allison Johnson Corplex Donepezil Transdermal System Corium International Inc. Gurnet...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...nivolumab Squamous and non-squamous non-small cell lung cancer (NSCLC) Ph III CheckMate -227 data April Corium International Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...rucaparib Maintenance in recurrent, platinum-sensitive ovarian cancer, regardless of BRCA mutation status Submit MAA 2Q18 Corium International Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...TSX:TRIL; NASDAQ:TRIL) 5/26/17 $31.0 $54.0 $47.5 -12% Achaogen Inc. (NASDAQ:AKAO) 5/25/17 $112.5 $919.2 $887.8 -3% Corium International Inc....
BioCentury | May 26, 2017
Financial News

Corium raises $35M in follow-on

...Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $35 million on May 25 through the sale of 5.6...
...Jefferies, Guggenheim Securities, Needham, FBR, H.C. Wainwright and WBB Securities. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Alex Himes Corium International Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...NASDAQ:IDXG) 2/3/17 $3.9 $14.9 $17.7 19% Neos Therapeutics Inc. (NASDAQ:NEOS) 2/3/17 $28.8 $109.1 $162.4 49% Corium International Inc....
BioCentury | Feb 3, 2017
Financial News

Corium completes follow-on

...Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $20 million through the sale of 6.7 million shares at...
...in a follow-on underwritten by Cantor Fitzgerald on Feb. 2. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Alex Himes Corium International Inc....
BioCentury | Jan 18, 2017
Clinical News

AQS1301: Clinical trial started

...to evaluate once-weekly transdermal AQS1301 for 4 weeks in 8 healthy male volunteers. Aequus and Corium...
...Transdermal Research (see BioCentury, Oct. 7, 2013 ). Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C. Corium International Inc....
...Endpoint: Safety and bioavailability Status: Clinical trial started Milestone: Clinical trial data (1Q17) Julian Zhu AQS-1301 AQS1301 Aequus Pharmaceuticals Inc. Corium International Inc. Transdermal...
Items per page:
1 - 10 of 30
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...of Danforth Advisors, who served as interim CFO. Breuil was CFO of specialty transdermal company Corium...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Another Shire veteran, Perry Sternberg, has become CEO of Corium International Inc....
...remain chairman. The move comes about four months after affiliates of Gurnet Point Capital acquired Corium...
...Corp. (NASDAQ:QTRX). BioCentury Staff Agios Pharmaceuticals Inc. Bio-Rad Laboratories Inc. Biohaven Pharmaceutical Holding Co. Ltd. CASI Pharmaceuticals Inc. Centogene N.V. Collegium Pharmaceutical Inc. Corium International Inc. Enterome...
BioCentury | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

...Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share...
...transaction, Corium will also offer to repurchase all of its $120 million in convertible notes. Corium's...
...Gurnet Point Capital, Cambridge, Mass. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Business: Neurology Allison Johnson Corplex Donepezil Transdermal System Corium International Inc. Gurnet...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...nivolumab Squamous and non-squamous non-small cell lung cancer (NSCLC) Ph III CheckMate -227 data April Corium International Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...rucaparib Maintenance in recurrent, platinum-sensitive ovarian cancer, regardless of BRCA mutation status Submit MAA 2Q18 Corium International Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...TSX:TRIL; NASDAQ:TRIL) 5/26/17 $31.0 $54.0 $47.5 -12% Achaogen Inc. (NASDAQ:AKAO) 5/25/17 $112.5 $919.2 $887.8 -3% Corium International Inc....
BioCentury | May 26, 2017
Financial News

Corium raises $35M in follow-on

...Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $35 million on May 25 through the sale of 5.6...
...Jefferies, Guggenheim Securities, Needham, FBR, H.C. Wainwright and WBB Securities. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Alex Himes Corium International Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...NASDAQ:IDXG) 2/3/17 $3.9 $14.9 $17.7 19% Neos Therapeutics Inc. (NASDAQ:NEOS) 2/3/17 $28.8 $109.1 $162.4 49% Corium International Inc....
BioCentury | Feb 3, 2017
Financial News

Corium completes follow-on

...Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $20 million through the sale of 6.7 million shares at...
...in a follow-on underwritten by Cantor Fitzgerald on Feb. 2. Corium International Inc. (NASDAQ:CORI), Menlo Park, Calif. Alex Himes Corium International Inc....
BioCentury | Jan 18, 2017
Clinical News

AQS1301: Clinical trial started

...to evaluate once-weekly transdermal AQS1301 for 4 weeks in 8 healthy male volunteers. Aequus and Corium...
...Transdermal Research (see BioCentury, Oct. 7, 2013 ). Aequus Pharmaceuticals Inc. (TSX-V:AQS; OTCQB:AQSZF), Vancouver, B.C. Corium International Inc....
...Endpoint: Safety and bioavailability Status: Clinical trial started Milestone: Clinical trial data (1Q17) Julian Zhu AQS-1301 AQS1301 Aequus Pharmaceuticals Inc. Corium International Inc. Transdermal...
Items per page:
1 - 10 of 30